Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist’s Perspective

Antibody-drug conjugates (ADCs) appear to be in a developmental boom, with five FDA approvals in the last two years and a projected market value of over $4 billion by 2024. Major advancements in the engineering of these novel cytotoxic drug carriers have provided a few early success stories. Althoug...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucas, Andrew T., Moody, Amber, Schorzman, Allison N., Zamboni, William C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395454/
https://www.ncbi.nlm.nih.gov/pubmed/34449544
http://dx.doi.org/10.3390/antib10030030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395454/
https://www.ncbi.nlm.nih.gov/pubmed/34449544
http://dx.doi.org/10.3390/antib10030030

Ejemplares similares